$RVMD

Revolution Medicines, Inc.

Runway:16 mo

NasdaqMarket cap: —CIK 0001628171

Upcoming catalysts

1 surfaced

“The Company intends to submit these data to global regulatory authorities, including to the U.S. Food and Drug Administration as part of a future New Drug Application under a Commissioner's National Priority Voucher.”

Date TBD

Drug pipeline

RMC-5127

Non-small Cell Lung Cancer (NSCLC)

Elironrasib

Non-Small Cell Lung Cancer (NSCLC)

RMC-6291

Non-Small Cell Lung Cancer (NSCLC)

RMC-6236

Pancreatic Cancer

Daraxonrasib

Advanced Solid Tumors

RMC-4630

Solid Tumor

RMC-5552

Solid Tumors

RMC-9805

Non-small Cell Lung Cancer (NSCLC)

Zoldonrasib

Pancreatic Cancer

Recent & active trials

NCT	Drug	Phase	Status	Primary completion
NCT07252232	Daraxonrasib	Phase 3	Recruiting	2029-05-10
NCT07397338	Daraxonrasib	Phase 2	Recruiting	2029-05-01
NCT07621718	Zoldonrasib	Phase 3	Recruiting	2028-12-30
NCT06128551	Elironrasib	Phase 2	Recruiting	2028-12-01
NCT07491445	Daraxonrasib	Phase 3	Recruiting	2028-06-01
NCT07349537	RMC-5127	Phase 1	Recruiting	2028-04-01
NCT06881784	Daraxonrasib	Phase 3	Recruiting	2027-12-01
NCT06162221	RMC-6291	Phase 2	Recruiting	2027-06-01
NCT05379985	RMC-6236	Phase 2	Recruiting	2027-05-31
NCT06445062	RMC-6236	Phase 2	Recruiting	2027-05-15
NCT05462717	RMC-6291	Phase 1	Active Not Recruiting	2027-03-31
NCT06040541	RMC-9805	Phase 1	Recruiting	2026-12-31
NCT06625320	RMC-6236	Phase 3	Active Not Recruiting	2026-06-01
NCT05054725	RMC-4630	Phase 2	Completed	2024-07-03
NCT04774952	RMC-5552	Phase 1	Completed	2024-05-06
NCT03634982	RMC-4630	Phase 1	Unknown	2023-03-31
NCT03989115	RMC-4630	Phase 2	Completed	2022-02-08
NCT07573215	Daraxonrasib	—	Available	—